The Effects of Resveratrol Supplementation on Inflammation and Cognitive Performance in Healthy Adults

Cognitive Change Clinical Trial

Official title:

The Acute and Chronic Effects of Resveratrol Supplementation on Inflammation and Cognitive Performance in Healthy Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04314739
• Other study ID #: 52P7
• Status: Completed
• Phase: N/A
• Start date: March 19, 2019
• Est. completion date: December 19, 2019

Study information

• Verified date: March 2019
• Source: Northumbria University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Previous research has suggested that high levels of systemic inflammation can contribute to cognitive deficits and additional health problems; consumption of polyphenols have been shown to have an anti-inflammatory effect. Resveratrol, a polyphenol found primarily in red grape skins, has previously been shown to improve brain blood flow and possibly brain function and may potentially reduce systemic inflammation, however there is limited research into this.

This study will investigate the effects of 4 weeks daily consumption of resveratrol on inflammation and cognitive function in healthy adults.

Description:

Each participant will be required to attend the laboratory on three occasions. The first of these will be an initial screening/training visit, this will take place in the afternoon and last 2 1/2 hours in total. During the initial visit participants will be asked to provide written informed consent. They will provide lifestyle and demographic data and screened regards to physical health (height, weight, blood pressure, waist to hip ratio). They will then complete a food frequency questionnaire and be trained on the computerised cognitive and mood tasks. Participants will also be trained on completing the cognitive assessment battery on their mobile phone, they will complete a further 5 assessments on their phone, once the day before their first visit and every 7 days during the supplementation period.

Study days 1 and 2 (4 weeks apart) :

Participants will arrive at the laboratory at an agreed time in the morning (7am, 8.30am or 10am) having fasted for 12 hours, avoided caffeinated products for 18 hours, alcohol and over the counter medication for 24 hours and oral antihistamines for 48 hours prior to the session commencing.

Participants will provide a blood sample, they will then complete a short computerised cognitive assessment (~20 minutes in length), followed by measurements of blood pressure and heart rate. Following this the participants will consume their treatment for the day, followed by a 40 minute absorption period and then will complete the second cognitive assessment. Participants will then provide a second blood sample. At the end of the first study session participants will be provided with their treatment and treatment diary, they will be instructed to take one tablet twice a day (30 minutes after breakfast and dinner). Both study visits will be identical and will take place 29 days (+/- 2 days) apart.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: December 19, 2019
• Est. primary completion date: December 19, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Participants must self-assess themselves as being in good health.

• Aged 18 to 55 at the time of giving consent

Exclusion Criteria:

• Have a Body Mass Index (BMI) outside the range of 18.5-42kg/m2

Related Conditions & MeSH terms

• Cognitive Change
• Inflammation
• Mood
• Systemic Inflammation

Intervention

Dietary Supplement:
• Resveratrol
Participants will consume one of the treatment types daily for a period of four weeks.
• Placebo
Participants will consume one of the treatment types daily for a period of four weeks.

Locations

Country	Name	City	State
United Kingdom	Northumbria University	Newcastle Upon Tyne	Tyne And Wear

Sponsors (2)

Lead Sponsor	Collaborator
Northumbria University	Evolva SA

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline concentration of biomarkers of systemic inflammation	Assessment of change from baseline: C reactive protein, tumor necrosis factor alpha and interleukin 6.	1 hour post dose; 4 weeks
Secondary	Acute changes in cognitive task performance	This will be assessed using a computerised cognitive battery (administered using COMPASS cognitive assessment program). Changes in episodic memory, working memory, spatial memory, executive function and attention as compared to pre-treatment performance on day 1. All tasks have the same x3 outcome measures; accuracy (% correct), errors (% incorrect) and speed (milliseconds) and the individual task scores will therefore be collapsed into global cognitive domains.	40 minutes post dose
Secondary	Interim changes in cognitive task performance	This will be assessed using a computerised cognitive battery, this will be administered using 'Cognimapp'mobile phone program, participants will complete this battery away from home using their own mobile phone. Changes in attention, executive function, working memory and episodic memory as compared to performance on Day -1. All tasks have the same x3 outcome measures; accuracy (% correct), errors (% incorrect) and speed (milliseconds) and the individual task scores will therefore be collapsed into global cognitive domains.	Day 7; Day 14; Day 21; Day 28
Secondary	Chronic changes in cognitive task performance	This will be assessed using a computerised cognitive battery (administered using COMPASS cognitive assessment program). Changes in episodic memory, working memory, spatial memory, executive function and attention as compared to pre-treatment performance on day 1. All tasks have the same x3 outcome measures; accuracy (% correct), errors (% incorrect) and speed (milliseconds) and the individual task scores will therefore be collapsed into global cognitive domains.	4 weeks
Secondary	Acute changes in mood	Assessed using Visual Analogue Mood Scales at each assessment during each cognitive assessment. Participants will complete 27 separate visual analogue mood scales that load onto 3 mood outcomes: Alertness, Stress and Tranquillity (the individual scale results are averaged to create this score). A score between 0 and 100 can be obtained, where a higher value indicates that the participant felt more Alert, Stressed or Tranquil.	40 mins post dose
Secondary	Interim changes in mood	Assessed using Visual Analogue Mood Scales at each assessment during the interim supplementation period. Participants will complete 27 separate visual analogue mood scales that load onto 3 mood outcomes: Alertness, Stress and Tranquillity (the individual scale results are averaged to create this score). A score between 0 and 100 can be obtained, where a higher value indicates that the participant felt more Alert, Stressed or Tranquil.	Day 7; Day 14; Day 21; Day 28
Secondary	Chronic changes in mood	Assessed using the Profile of Mood States questionnaire, completed at the start of each testing visit. The questionnaire includes 65 items and participants rate their mood on a scale of 0-4 (not at all - extremely). These scores are collapsed into 6 mood outcomes (Tension, depression, anger, vigour, fatigue and confusion) and a total mood disturbance score.	4 weeks
Secondary	Acute changes in concentration of plasma and serum biomarkers	Biomarkers of insulin, glucose, cholesterol and resveratrol metabolites will be measured in plasma and serum using liquid chromatography-mass spectrometry and ELISA analysis in association with other endpoints.	1 hour post dose
Secondary	Chronic changes in concentration of plasma and serum biomarkers	Biomarkers of insulin, glucose, cholesterol and resveratrol metabolites will be measured in plasma and serum using liquid chromatography-mass spectrometry and ELISA analysis in association with other endpoints.	4 weeks
Secondary	Acute and chronic changes in blood pressure	Systolic and diastolic blood pressure will be taken after each cognitive assessment (measured in mm Hg).	1 hour post dose, 4 weeks
Secondary	Acute and chronic changes in heart rate	Heart rate will be measured after each cognitive assessment (measured in BPM).	1 hour post dose, 4 weeks
Secondary	Changes in weight and Body Mass Index (BMI)	Participants weight will be recorded at testing visits and BMI will be calculated.	4 weeks